Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 12/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 10/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.64 |
| ▸ | QPCT | Q16769 | 1/20 | 0.64 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.64 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.64 |
| ▸ | FNTA | P49354 | 1/20 | 0.57 |
| ▸ | FNTB | P49356 | 1/20 | 0.57 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394308 | 0.88 | CYP11B1 (0.83) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL1719741 | 0.84 | CYP11B1 (0.72) | CYP11B1CYP11B2ADRA2CCYP19A1 | |
| SCHEMBL31060578 | 0.82 | CYP11B1 (0.70) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL17407550 | 0.82 | CYP11B1 (0.70) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL24733003 | 0.80 | CYP11B1 (0.71) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL9661609 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL12205 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL30448042 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL860653 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL10997898 | 0.80 | CYP11B1 (0.71) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | claimed |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY | 2020-06-04 | — | — | US | claimed |
| WO-2018213821-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY (US) | 2018-11-22 | — | — | WO | claimed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | claimed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | claimed |
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY | 2020-06-04 | — | — | US | disclosed |
| WO-2018213821-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY (US) | 2018-11-22 | — | — | WO | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2010066658-A1 | COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010026365-A1 | N-MYRISTOYL TRANSFERASE INHIBITORS | UNIVERSITY OF DUNDEE (GB) | 2010-03-11 | — | — | WO | disclosed |
| EP-0281121-B1 | 1-(1-ARYL-2-HYDROXY-ETHYL)-IMIDAZOLES AND THEIR SALTS, PROCESSES FOR THEIR PREPARATION, DRUGS CONTAINING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-04-29 | — | — | EP | disclosed |
| US-4999352-A | Antidepressants or fungicides | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-12 | — | — | US | disclosed |
| EP-0281121-A1 | 1-(1-Aryl-2-hydroxy-ethyl)-imidazoles and their salts, processes for their preparation, drugs containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4431815-A | CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | MLX, LDHA, CA2 | CYP11B1 2753/4885CYP11B2 2830/4885ADRA2C 1778/4885 |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | MLX, LDHA, CA2 | CYP11B1 2753/4885CYP11B2 2830/4885ADRA2C 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.